Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity

A new mathematical model for relative quantification in real-time RT-PCR

Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · see citing works

Fibroblasts in cancer

Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · see citing works

The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses

Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 3,935 · see citing works

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works

GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists

Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356 · see citing works

Determination of subcutaneous tumor size in athymic (nude) mice

Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830 · see citing works

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515 · see citing works

RNA Polymerase III Detects Cytosolic DNA and Induces Type I Interferons through the RIG-I Pathway

Chiu, Y., MacMillan, J. B., & Chen, Z. J. (2009) · Cell · doi:10.1016/j.cell.2009.06.015 · Cited by 1,185 · see citing works

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · see citing works

Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression

Hwang, R. F., Moore, T. T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A. M., Ji, B., Evans, D. B., & Logsdon, C. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5714 · Cited by 1,093 · see citing works

Cancer immunoediting from immune surveillance to immune escape

Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,078 · see citing works

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl, D., Lichty, B., TENOEVER, B., Paterson, J., Power, A., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 894 · see citing works

RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III–transcribed RNA intermediate

Ablasser, A., Bauernfeind, F. G., Hartmann, G., Latz, E., Fitzgerald, K. A., & Hornung, V. (2009) · Nature Immunology · doi:10.1038/ni.1779 · Cited by 892 · see citing works

Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression

Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807 · see citing works

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793 · see citing works

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

Heo, J., Reid, T. R., Ruo, L., Breitbach, C. J., Rose, S. C., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 781 · see citing works

Sample Size Determination

Dell, R. B., Holleran, S., & Ramakrishnan, R. (2002) · ILAR Journal · doi:10.1093/ilar.43.4.207 · Cited by 746 · see citing works

The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications

Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.115 · Cited by 662 · see citing works

Going viral with cancer immunotherapy

Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3770 · Cited by 590 · see citing works

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

Breitbach, C. J., Burke, J., Jonker, D. J., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J. J., Hwang, T.-H., Moon, A., Patt, R. H., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 552 · see citing works

Cancer-associated fibroblasts and tumor growth – bystanders turning into key players

Östman, A., & Augsten, M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.003 · Cited by 542 · see citing works

Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia.

Rønnov‐Jessen, L., & PETERSEN, O. W. (1993) · PubMed · Cited by 514 · see citing works

Cancer associated fibroblasts: the dark side of the coin.

Cirri, P., & Chiarugi, P. (2011) · Europe PMC (PubMed Central) · Cited by 501 · see citing works

Activation of fibroblasts in cancer stroma

Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499 · see citing works

Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance

Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 477 · see citing works

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · see citing works

Cancer associated fibroblasts in cancer pathogenesis

Franco, O. E., Shaw, A. K., Strand, D. W., & Hayward, S. W. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.10.010 · Cited by 395 · see citing works

AltAnalyze and DomainGraph: analyzing and visualizing exon expression data

Emig, D., Salomonis, N., Baumbach, J., Lengauer, T., Conklin, B. R., & Albrecht, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq405 · Cited by 324 · see citing works

Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma.

Löhr, M. J., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H., & Jesnowski, R. (2001) · PubMed · Cited by 323 · see citing works

Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF

Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M.-S., Je, J.-E., Yoon, J., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303 · see citing works

INTERFEROME: the database of interferon regulated genes

Samarajiwa, S., Forster, S. C., Auchettl, K., & Hertzog, P. J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn732 · Cited by 266 · see citing works

Targeting Tumor Vasculature With an Oncolytic Virus

Breitbach, C. J., Silva, N. S. D., Falls, T. J., Aladl, U. E., Evgin, L., Paterson, J. M., Sun, Y., Roy, D. G., Rintoul, J. L., Daneshmand, M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.26 · Cited by 204 · see citing works

Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy

Kurozumi, K., Hardcastle, J. J., Thakur, R., Yang, M., Christoforidis, G. A., Fulci, G., Hochberg, F. H., Weissleder, R., Carson, W. E., Chiocca, E. A., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm229 · Cited by 172 · see citing works

Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus

Brun, J., McManus, D. C., Lefebvre, C. A., Hu, K., Falls, T. J., Atkins, H. L., Bell, J. C., McCart, J. A., Mahoney, D. J., & Stojdl, D. F. (2010) · Molecular Therapy · doi:10.1038/mt.2010.103 · Cited by 153 · see citing works

Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery

Lisanti, M. P., Martinez‐Outschoorn, U., & Sotgia, F. (2013) · Cell Cycle · doi:10.4161/cc.25695 · Cited by 119 · see citing works

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

Sobol, P. T., Boudreau, J., Stephenson, K., Wan, Y., Lichty, B., & Mossman, K. (2011) · Molecular Therapy · doi:10.1038/mt.2010.264 · Cited by 104 · see citing works

The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance

Erkan, M., Reiser–Erkan, C., Michalski, C. W., Kong, B., Esposito, I., Frieß, H., & Kleeff, J. H. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218921 · Cited by 88 · see citing works

ICP0 Gene Expression Is a Herpes Simplex Virus Type 1 Apoptotic Trigger

Sanfilippo, C. M., & Blaho, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.00334-06 · Cited by 77 · see citing works

Expression of FGF-2 in neural progenitor cells enhances their potential for cellular brain repair in the rodent cortex

Dayer, A. G., Jenny, B., Sauvain, M.-O., Potter, G., Salmon, P., Zgraggen, E., Kanemitsu, M., Gascon, E., Sizonenko, S. V., Trono, D., et al. (2007) · Brain · doi:10.1093/brain/awm200 · Cited by 75 · see citing works

Abnormal properties of skin fibroblasts from patients with breast cancer

Azzarone, B. G., Mareel, M., Billard, C., Scemama, P., Chaponnier, C., & Macieira‐Coelho, A. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910330608 · Cited by 74 · see citing works

Fibroblasts from cancer patients display a mixture of both foetal and adult-like phenotypic characteristics

Schor, S. L., Schor, A. M., & Rushton, G. (1988) · Journal of Cell Science · doi:10.1242/jcs.90.3.401 · Cited by 72 · see citing works

Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?

Stanford, M. M., Breitbach, C. J., Bell, J. C., & McFadden, G. (2008) · PubMed · Cited by 44 · see citing works

Fetal myofibroblast‐like cells isolated from post‐radiation fibrosis in human breast cancer

Brouty‐Boyé, D., Raux, H., Azzarone, B. G., Tamboise, A., Tamboise, E., Beranger, S., Magnien, V., Pihan, I., Zardi, L., & Israël, L. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470512 · Cited by 37 · see citing works

Review of “An Interleukin-17-Mediated Paracrine Network Promotes Tumor Resistance to Anti-Angiogenic Therapy” by Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N in Nat Med 19

Pickrell, B. B., Bhadkamkar, M. A., & Hollier, L. H. (2014) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000000688 · Cited by 32 · see citing works

Sorting Out Pandora’s Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma

Altomonte, J., & Ebert, O. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00085 · Cited by 11 · see citing works

Oncolytic viruses as engineering platforms for combination immunotherapy

Twumasi‐Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 423 · see citing works

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

Bommareddy, P. K., Patel, A. V., Hossain, S., & Kaufman, H. L. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0238-9 · Cited by 323 · see citing works

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Tian, Y., Xie, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 304 · see citing works

Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives

Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12392 · Cited by 292 · see citing works

Trial watch

Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255 · see citing works

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies

Gujar, S. A., Pol, J. G., Kim, Y., Lee, P. W. K., & Kroemer, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 234 · see citing works

Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade

Nakao, S., Arai, Y., Tasaki, M., YAMASHITA, M., Murakami, R., Kawase, T., Amino, N., Nakatake, M., Kurosaki, H., Mori, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7992 · Cited by 191 · see citing works

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy

Achard, C., Surendran, A., Wedge, M.-È., Ungerechts, G., Bell, J. C., & Ilkow, C. S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.020 · Cited by 152 · see citing works

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

Yu, G., Wu, Y., Wang, W., Xu, J., Lv, X., Cao, X., & Wan, T. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0026-y · Cited by 147 · see citing works

Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones

Martin, N. T., & Bell, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.001 · Cited by 148 · see citing works

Past, Present and Future of Oncolytic Reovirus

Müller, L. M. E., Berkeley, R. A., Barr, T., Ilett, E. J., & Errington‐Mais, F. (2020) · Cancers · doi:10.3390/cancers12113219 · Cited by 129 · see citing works

Vascular mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma

Yang, J., Yang, L., Lin, Y., Zheng, Z., Fang, J., He, S., & Zhuang, S. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.012 · Cited by 127 · see citing works

Oncolytic viruses: overcoming translational challenges

Martínez‐Quintanilla, J., Seah, I. Y. J., Chua, M. M. J., & Shah, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122287 · Cited by 119 · see citing works

Prospects for combined use of oncolytic viruses and CAR T-cells

Ajina, A., & Maher, J. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0294-6 · Cited by 117 · see citing works

Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy

Hou, W., Sampath, P., Rojas, J. J., & Thorne, S. H. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.012 · Cited by 115 · see citing works

Trial Watch—Oncolytic viruses and cancer therapy

Pol, J. G., Buqué, A., Aranda, F., Bloy, N., Cremer, I., Eggermont, A. M. M., Erbs, P., Fucikova, J. P., Galon, J., Limacher, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1117740 · Cited by 111 · see citing works

Oncolytic Viruses: Exploiting Cancer's Deal with the Devil

Pikor, L. A., Bell, J. C., & Diallo, J. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.004 · Cited by 109 · see citing works

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

Heidbuechel, J. P. W., & Engeland, C. E. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01075-5 · Cited by 109 · see citing works

Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients

Zhong, L., Gan, L., Wang, B., Wu, T., Yao, F., Gong, W., Peng, H., Deng, Z., Xiao, G., Liu, X., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.010 · Cited by 107 · see citing works

Oncolytic Viruses: Therapeutics With an Identity Crisis

Breitbach, C. J., Lichty, B. D., & Bell, J. C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.046 · Cited by 102 · see citing works

Breast Cancer Cell–Derived Soluble CD44 Promotes Tumor Progression by Triggering Macrophage IL1β Production

Jang, J., Kim, D.-H., Lim, J. M., Lee, J. W., Jeong, S. J., Kim, K. P., & Surh, Y. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2288 · Cited by 105 · see citing works

Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment

Wang, L., Chard, L. S., Cheng, Z., & Wang, Y. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004167 · Cited by 100 · see citing works

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

Rezaei, R., Ghaleh, H. E. G., Farzanehpour, M., Dorostkar, R., Ranjbar, R., Bolandian, M., Nodooshan, M. M., & Alvanegh, A. G. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00359-9 · Cited by 98 · see citing works

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

Chen, L., Zuo, M., Zhou, Q., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308890 · Cited by 92 · see citing works

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives

Guo, Z. S., Liu, Z., Kowalsky, S. J., Feist, M., Kaliński, P., Lu, B., Storkus, W. J., & Bartlett, D. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00555 · Cited by 90 · see citing works

STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy

Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90 · see citing works

Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds

Selman, M., Rousso, C., Bergeron, A., Son, H. H., Krishnan, R., El-Sayes, N., Varette, O., Chen, A., Bœuf, F. L., Tzelepis, F., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.014 · Cited by 90 · see citing works

Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study

Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. L., & Rommelaere, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01848 · Cited by 91 · see citing works

Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy

Fang, C., Xiao, G., Wang, T., Li, S., Peng, B., Xu, B., & Zhang, K. (2023) · Research · doi:10.34133/research.0108 · Cited by 79 · see citing works

Computer‐assisted engineering of hyperstable fibroblast growth factor 2

Dvořák, P., Bednář, D., Vaňáček, P., Bálek, L., Eiselleová, L., Štěpánková, V., Šebestová, E., Bosakova, M. K., Konečná, Ž., Mazurenko, S., et al. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26531 · Cited by 77 · see citing works

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Pol, J. G., Lévesque, S., Workenhe, S. T., Gujar, S. A., Bœuf, F. L., Clements, D. R., Fahrner, J., Fend, L., Bell, J. C., Mossman, K. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1503032 · Cited by 77 · see citing works

Gallbladder cancer-associated fibroblasts promote vasculogenic mimicry formation and tumor growth in gallbladder cancer via upregulating the expression of NOX4, a poor prognosis factor, through IL-6-JAK-STAT3 signal pathway

Pan, M., Wang, H., Ansari, K. H., Li, X., Sun, W., & Fan, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01742-4 · Cited by 77 · see citing works

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Guo, Z. S., Lotze, M. T., Zhu, Z., Storkus, W. J., & Song, X. (2020) · Biomedicines · doi:10.3390/biomedicines8070204 · Cited by 74 · see citing works

Targeting type I collagen for cancer treatment

Shi, R., Zhang, Z., Zhu, A.-K., Xiong, X., Zhang, J., Xu, J., Sy, M., & Li, C. (2022) · International Journal of Cancer · doi:10.1002/ijc.33985 · Cited by 71 · see citing works

Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy

Ban, W., Guan, J., Huang, H., He, Z., Sun, M., Liu, F., & Sun, J. (2022) · Nano Research · doi:10.1007/s12274-021-4031-6 · Cited by 69 · see citing works

Potentiating prostate cancer immunotherapy with oncolytic viruses

Lee, P. C., & Gujar, S. A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.10 · Cited by 69 · see citing works

Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses

Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 67 · see citing works

Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy

Liu, K., Kong, L., Cui, H., Zhang, L., Xin, Q., Zhuang, Y., Guo, C., Yao, Y., Tao, J., Gu, X., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101751 · Cited by 72 · see citing works

Cytokines in oncolytic virotherapy

Pol, J. G., Workenhe, S. T., Konda, P., Gujar, S. A., & Kroemer, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.007 · Cited by 68 · see citing works

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy

Durham, N. M., Mulgrew, K. A., McGlinchey, K., Monks, N. R., Ji, H. T., Herbst, R., Suzich, J., Hammond, S. A., & Kelly, E. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.006 · Cited by 66 · see citing works

Quantification of cell viability and rapid screening anti-cancer drug utilizing nanomechanical fluctuation

Wu, S., Liu, X., Zhou, X., Liang, X. M., Gao, D., Liu, H., Zhao, G., Zhang, Q., & Wu, X. (2016) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.09.024 · Cited by 64 · see citing works

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Oh, C., Chon, H. J., & Kim, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207743 · Cited by 62 · see citing works

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics

McCloskey, C. W., Rodriguez, G. M., Galpin, K. J. C., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080244 · Cited by 61 · see citing works

Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments

Yan, Z., Zhang, Z., Chen, Y., Xu, J., Wang, J., & Wang, Z. W. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03424-z · Cited by 58 · see citing works

Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy

Wedge, M.-È., Jennings, V. A., Crupi, M. J. F., Poutou, J., Jamieson, T. R., Pelin, A., Pugliese, G., de Souza, C. T., Petryk, J., Laight, B. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29526-8 · Cited by 55 · see citing works

An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment

DePeaux, K., Rivadeneira, D. B., Lontos, K., Dean, V. G., Gunn, W. G., Watson, M. J., Yao, T., Wilfahrt, D. N., Hinck, C. S., Wieteska, Ł., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230053 · Cited by 54 · see citing works

Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma

Li, M., Li, G., Kiyokawa, J., Tirmizi, Z. A., Richardson, L. G., Ning, J., Das, S., Martuza, R. L., Stemmer-Rachamimov, A. O., Rabkin, S. D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01096-0 · Cited by 54 · see citing works

Oncolytic viruses—immunotherapeutics on the rise

Keller, B. A., & Bell, J. C. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1453-9 · Cited by 52 · see citing works

The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy?

Zhang, S., & Rabkin, S. D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1850689 · Cited by 52 · see citing works

Virotherapy: From single agents to combinatorial treatments

Malfitano, A. M., Somma, S. D., Iannuzzi, C. A., Pentimalli, F., & Portella, G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113986 · Cited by 51 · see citing works

A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns

Loessner, D., Rockstroh, A., Shokoohmand, A., Holzapfel, B. M., Wagner, F., Baldwin, J., Boxberg, M., Schmalfeldt, B., Lengyel, E. R., Clements, J. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.014 · Cited by 50 · see citing works

Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis

Bhatt, D., Chammas, R. J., & Daemen, T. (2021) · Vaccines · doi:10.3390/vaccines9101166 · Cited by 48 · see citing works

Oncolytic viruses: advanced strategies in cancer therapy

Xiao, D., Zhang, H., Liu, Y., Li, Y., Li, G., & Ning, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02343-3 · Cited by 48 · see citing works

Microbiota in cancer: current understandings and future perspectives

Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 52 · see citing works

Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

Jin, K., Du, W., Liu, Y., Lan, H., Si, J., & Mou, X. (2021) · Cancers · doi:10.3390/cancers13040588 · Cited by 46 · see citing works

Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses

Everts, A., Bergeman, M. H., McFadden, G., & Kemp, V. (2020) · Biomedicines · doi:10.3390/biomedicines8110474 · Cited by 45 · see citing works

Oncolytic Virotherapy and the Tumor Microenvironment

Berkey, S. E., Thorne, S. H., & Bartlett, D. L. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_11 · Cited by 43 · see citing works

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Draganov, D., Santidrián, A. F., Minev, I., Nguyen, D. H., Kilinc, M. O., Petrov, I. S., Vyalkova, A., Lander, E. B., Berman, M. H., Minev, B., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1829-z · Cited by 43 · see citing works

Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies

Rojas, J. J., Sampath, P., Bonilla, B., Ashley, A., Hou, W., Byrd, D., & Thorne, S. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.017 · Cited by 42 · see citing works

Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes

Rouanet, M., Lebrin, M., Gross, F., Bournet, B., Cordelier, P., & Buscail, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061231 · Cited by 42 · see citing works

The Interaction Between Human Papillomaviruses and the Stromal Microenvironment

Woodby, B. L., Scott, M. L., & Bodily, J. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.003 · Cited by 41 · see citing works

Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis

Wei, R., Lv, M., Li, F., Cheng, T., Zhang, Z., Jiang, G., Zhou, Y., Gao, R., Xiao, W., Lou, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18621 · Cited by 41 · see citing works

Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models

Esaki, S., Nigim, F., Moon, E., Luk, S. O., Kiyokawa, J., Curry, W. T., Cahill, D. P., Chi, A. S., Iafrate, A. J., Martuza, R. L., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30929 · Cited by 41 · see citing works

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Hutzen, B. J., Chen, C., Wang, P.-Y., Sprague, L., Swain, H. M., Love, J., Conner, J., Boon, L., & Cripe, T. P. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.09.001 · Cited by 40 · see citing works

TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway

Yang, T., Huang, T., Zhang, D., Wang, M., Wu, B., Shang, Y., Sattar, S., Ding, L., Liu, Y., Jiang, H., et al. (2019) · Aging · doi:10.18632/aging.102329 · Cited by 40 · see citing works

Current and emerging concepts for systemic treatment of metastatic colorectal cancer

Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · see citing works

Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential

Tong, J., Valdés, Y. R., Sivapragasam, M., Barrett, J. W., Bell, J. C., Stojdl, D. F., DiMattia, G. E., & Shepherd, T. G. (2017) · BMC Cancer · doi:10.1186/s12885-017-3600-2 · Cited by 38 · see citing works

Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses

Jafari, M., Kadkhodazadeh, M., Shapourabadi, M. B., Goradel, N. H., Shokrgozar, M. A., Arashkia, A., Abdoli, S., & Sharifzadeh, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012806 · Cited by 35 · see citing works

Viruses as nanomedicine for cancer

Yoo, S. Y., Badrinath, N., & Heo, J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s116447 · Cited by 35 · see citing works

Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer

Jing, Y., Chavez, V. A., Ban, Y. J., Acquavella, N., El-Ashry, D., Pronin, A. N., Chen, X., & Merchan, J. R. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0016 · Cited by 34 · see citing works

Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses

Crupi, M. J. F., Bell, J. C., & Singaravelu, R. (2019) · Stem Cells · doi:10.1002/stem.3004 · Cited by 35 · see citing works

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model

Dobson, C. C., Naing, T., Beug, S. T., Faye, M. D., Chabot, J., St‐Jean, M., Walker, D. E., LaCasse, E. C., Stojdl, D. F., Korneluk, R. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13849 · Cited by 34 · see citing works

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer

Lee, W. S., Lee, S. J., Lee, H. J., Yang, H., Go, E., Enkhtaivan, G., Song, K., Xiang, X., Park, D.-G., Alain, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53347-6 · Cited by 32 · see citing works

Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer

Crupi, M. J. F., Taha, Z., Janssen, T. J. A., Petryk, J., Boulton, S., Alluqmani, N., Jirovec, A., Kassas, O., Khan, S., Vallati, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029269 · Cited by 31 · see citing works

Lysyl oxidase activates cancer stromal cells and promotes gastric cancer progression: quantum dot-based identification of biomarkers in cancer stromal cells

Peng, C., Liu, J., Yang, G., & Li, Y. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s143871 · Cited by 31 · see citing works

Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer

Malfitano, A. M., Somma, S. D., Prevete, N., & Portella, G. (2019) · Cancers · doi:10.3390/cancers11101532 · Cited by 30 · see citing works

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

Liu, Y., Zheng, Y., Deng, T., Huang, Y., Liu, Z., Zhan, B., Zhou, X., Yan, R., Ren, J., Xing, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1037934 · Cited by 30 · see citing works

OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution

Kuhn, I., Bauzon, M., Green, N. H., Seymour, L. W., Fisher, K. D., & Hermiston, T. W. (2016) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.12.001 · Cited by 28 · see citing works

Fibroblast Growth Factor 2 Enhances Zika Virus Infection in Human Fetal Brain

Limonta, D., Jovel, J., Kumar, A., Lu, J., Hou, S., Airo, A. M., López-Orozco, J., Wong, C. P., Saito, L. B., Branton, W. G., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz073 · Cited by 26 · see citing works

High-throughput screening in multicellular spheroids for target discovery in the tumor microenvironment

Calpe, B., & Kovacs, W. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1756769 · Cited by 25 · see citing works

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions

Holbrook, M. C., Goad, D. W., & Grdzelishvili, V. Z. (2021) · Cancers · doi:10.3390/cancers13051171 · Cited by 24 · see citing works

Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy

Wang, X., Shen, Y., Wan, X., Hu, X., Cai, W.-Q., Wu, Z., Xin, Q., Liu, X., Gui, J., Xin, H.-Y., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04360-8 · Cited by 24 · see citing works

The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them

Hu, P.-Y., Fan, X., Zhang, Y.-N., Wang, S., Wan, W.-J., Pan, H., & Mou, X. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10802-w · Cited by 22 · see citing works

MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer

Singh, H. M., Leber, M. F., Bossow, S., Engeland, C. E., Dessila, J., Grossardt, C., Zaoui, K., Bell, J. C., Jäger, D., Kalle, C. V., et al. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.015 · Cited by 22 · see citing works

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy

Schirrmacher, V., Gool, S. V., & Stuecker, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113050 · Cited by 22 · see citing works

Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs

Innao, V., Rizzo, V., Allegra, A. G., Musolino, C., & Allegra, A. (2020) · Current Oncology · doi:10.3390/curroncol28010019 · Cited by 22 · see citing works

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

Ageenko, A. B., Vasileva, N. S., Richter, V. A., & Kuligina, E. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042042 · Cited by 21 · see citing works

Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence

Chen, J., Madina, B. R., Ahmadi, E., Yarovinsky, T. O., Krady, M. M., Meehan, E. V., Wang, I. C., Ye, X., Pitmon, E., Ma, X., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.034 · Cited by 20 · see citing works

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

Müller, L. M. E., Migneco, G., Scott, G. B., Down, J. M., King, S., Askar, B., Jennings, V. A., Oyajobi, B. O., Scott, K. J., West, E. J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001803 · Cited by 20 · see citing works

Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms

Chen, J., Zhang, H., Zhou, L., Hu, Y., Li, M., He, Y., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584367 · Cited by 19 · see citing works

Synergistic combination of oncolytic virotherapy with CAR T-cell therapy

Ajina, A., & Maher, J. F. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.015 · Cited by 20 · see citing works

Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus

Harryvan, T. J., Golo, M., van Dam, N. M., Schoonderwoerd, M. J. A., Farshadi, E. A., Hornsveld, M., Hoeben, R. C., Hawinkels, L. J. A. C., & Kemp, V. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00507-9 · Cited by 17 · see citing works

Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer

Zhao, J., Wang, H., Wang, C., Li, F., Chen, J., Zhou, F., Zhu, Y., Chen, J., Liu, J., Zheng, H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.017 · Cited by 17 · see citing works

Viro-immune therapy: A new strategy for treatment of pancreatic cancer

Ibrahim, A. M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.748 · Cited by 17 · see citing works

Advances and Challenges of Nanoparticle-Based Macrophage Reprogramming for Cancer Immunotherapy

Kapitanova, K., Naumenko, V., Garanina, A. S., Melnikov, P., Abakumov, M. A., & Alieva, I. B. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919070058 · Cited by 17 · see citing works

Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

Naumenko, V., Stepanenko, A. A., Lipatova, A. V., Vishnevskiy, D. A., & Chekhonin, V. P. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.004 · Cited by 16 · see citing works

Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer

Mistarz, A., Winkler, M., Battaglia, S., Liu, S., Hutson, A. D., Rokita, H., Gambotto, A. A., Odunsi, K. O., Singh, P. K., McGray, A. R., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.02.002 · Cited by 15 · see citing works

Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment

Surendran, A., Jamalkhah, M., Poutou, J., Birtch, R., Lawson, C., Dave, J., Crupi, M. J. F., Mayer, J., Taylor, V., Petryk, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1099459 · Cited by 15 · see citing works

The Next Frontier of Oncotherapy: Accomplishing Clinical Translation of Oncolytic Bacteria Through Genetic Engineering

Dailey, K. M., Allgood, J. E., Johnson, P. R., Ostlie, M. A., Schaner, K., Brooks, B. D., & Brooks, A. E. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0245 · Cited by 15 · see citing works

Macrophages and their interactions with oncolytic viruses

Jakeman, P. G., Hills, T. E., Fisher, K. D., & Seymour, L. W. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.06.007 · Cited by 15 · see citing works

A cross-talk network that facilitates tumor virotherapy

Bronisz, A., & Chiocca, E. A. (2015) · Nature Medicine · doi:10.1038/nm.3857 · Cited by 1 · see citing works

Crosstalk between Tumor Cells and CAFs Enhances Oncolytic Virus Activity

(2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2015-079

Therapeutic targeting of cancer-associated fibroblasts with oncolytic virus in preclinical models of intrahepatic cholangiocarcinoma

Abeynayake, A. M., Rengers, T. A., Carlson, D. M., Abdelrahman, A. M., Maroun, J. W., Jalan‐Sakrikar, N., Penza, V., Naik, S., Truty, M. J., Conboy, C. B., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201325

STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy

Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90 · see citing works

Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection

Dam, N., Ioannidis, G., Hawinkels, L. J. A. C., & Kemp, V. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2617274 · Cited by 1 · see citing works